WeissLaw LLP: Cytec Industries, Inc. Acquisition May Not Be In The Best Interest Of CYT Shareholders

Aug 06, 2015, 13:48 ET from WeissLaw LLP

NEW YORK, Aug. 6, 2015 /PRNewswire/ -- The fairness of the proposed acquisition of Cytec Industries, Inc. ("CYT" or the "Company") by Solvay S.A. ("Solvay") is the subject of an investigation by WeissLaw LLP, a national class action, shareholder rights law firm.  The investigation focuses on possible breaches of fiduciary duty and other violations of law by the Board of Directors of CYT for agreeing to sell the Company to Solvay.  On July 29, 2015, the Company announced it had reached a definitive agreement for Solvay to acquire CYT in a transaction valued at approximately $5.5 billion.  Under the terms of the agreement, CYT shareholders will receive $75.25 for each CYT share they own. 

WeissLaw is investigating whether CYT's Board acted in the best interests of CYT's public shareholders by actively shopping the Company to maximize shareholder value prior to entering into the agreement with Solvay.  If you own CYT shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at (888) 593-4771 or by email at stockinfo@weisslawllp.com

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com or fill out the form on our website, http://www.weisslawllp.com/contact/report_fraud/.

Attorney Advertising.  Past results do not guarantee a similar outcome.